Evaluation of Triple Antibiotic Paste Pulp Therapy Compared to Vitapex in Primary Molars.
Launched by KING ABDULAZIZ UNIVERSITY · Sep 8, 2020
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
This study evaluated and compared the clinical and radiographic efficacy of non-instrumentation triple antibiotic paste pulp therapy (TAP) versus Vitapex pulpectomy in non-vital primary molars. Healthy 5 to 9 years old children with at least one non-vital primary molar were included in the study. molars were divided based on the subject's cooperation level and parental preference into two groups. In the first group, molars received TAP and in the second group, they received Vitapex pulpectomy followed by a stainless-steel crown. The TAP was freshly prepared and proportioned in equal parts b...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Primary molars with at least one of the following signs and symptoms were eligible and were included in the study:
- • badly decayed with signs of irreversible pulpitis,
- • necrosis and chronic infection such as: pain or tenderness to percussion and palpation, abscess, fistula-opening, gingival swelling, grade II and greater pathological tooth mobility, evidence of periapical/bifurcation radiolucency,
- • All the teeth included, had physiological root resorption of less than one third of the root.
- • Exclusion Criteria
- • Teeth showing radiographic evidence of excessive internal or external root resorption,
- • perforated pulpal floor,
- • excessive bone loss in furcation area involving the underlying tooth germ,
- • non- restorable teeth were excluded from the study.
About King Abdulaziz University
King Abdulaziz University (KAU) is a leading academic institution located in Jeddah, Saudi Arabia, renowned for its commitment to advancing medical research and innovation. As a prominent clinical trial sponsor, KAU leverages its extensive resources and expertise to facilitate groundbreaking studies aimed at improving healthcare outcomes. The university fosters collaboration among multidisciplinary teams of researchers, clinicians, and industry partners, ensuring adherence to rigorous ethical standards and regulatory requirements. KAU is dedicated to enhancing scientific knowledge and translating research findings into practical applications that benefit patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jeddah, Makkah, Saudi Arabia
Patients applied
Trial Officials
heba sabbagh, PhD
Principal Investigator
Assistant Professor, Department of Pediatric Dentistry King Abdulaziz University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials